Wider-Than-Expected Loss at Pharmacyclics

Zacks

Pharmacyclics Inc.’s (PCYC) first quarter 2013 loss of 73 cents per share was wider than the year-ago loss of 19 cents and the loss of 8 cents hinted at by the Zacks Consensus Estimate. The wider loss was attributable to higher costs incurred by the company during the first quarter of 2013.

Total revenue for the first quarter of 2013 climbed 47.7% to $2.8 million. Revenues during the quarter consisted solely of collaborative service revenues. Revenues were way below the Zacks Consensus Estimate of $20 million. Lower-than-expected revenues were also responsible for the wider-than-expected loss.

We note that Pharmacyclics received a clinical milestone payment of $50 million last month under its collaboration and license agreement with Janssen Biotech, a Johnson & Johnson (JNJ) company. This payment is not included in the first quarter 2013 results.

Pharmacyclics has received milestone payments of $200 million under its agreement with Janssen so far. Pharmacyclics is eligible to receive further payments up to $625 million under the agreement.

Pharmacyclics’ total operating expenses for the first quarter of 2013 jumped to $55.8 million from $19.9 million. The company’s general and administrative expenses increased 400% to $20 million while research and development expenses climbed 126.6% to $35.8 million.

The huge increase in operating costs was primarily attributable to the company’s efforts to develop its pipeline and increased personnel related costs.

Outlook

Pharmacyclics is looking to break even for the second quarter and the full year 2013.  While the Zacks Consensus Estimate for the second quarter of 2013 hints at earnings of 1 cent per share, it is a loss of 39 cents for full year 2013.

Our take

We expect investor focus to remain on the development of Pharmacyclics’ lead pipeline candidate ibrutinib. The candidate is being developed for multiple oncology indications in collaboration with Janssen.

Pharmacyclics, a biopharmaceutical company, carries a Zacks Rank #2 (Buy). Celgene Corporation (CELG) and Medivation, Inc. (MDVN) too carry a Zacks Rank #2 in the biopharma space.

Read the Full Research Report on CELG

Read the Full Research Report on MDVN

Read the Full Research Report on JNJ

Read the Full Research Report on PCYC

Zacks Investment Research



More From Zacks.com

Rates

View Comments (0)

Recommended for You

  • Apple's iPhone sales beat Street but iPad volumes slide

    Apple Inc (AAPL.O) forecast a strong holiday quarter after a better-than-expected 16 percent jump in iPhone sales, and the strongest growth in Mac computer shipments in years helped the company surpass Wall Street's targets. The company on Monday projected stronger-than-expected revenue of $63.5 billion to $66.5 billion in the December quarter, when new iPads and iPhones vie with rival devices from Microsoft Corp (MSFT.O) and Amazon.com Inc (AMZN.O) for consumers' holiday outlays. Shares of Apple rose 1.3 percent to about $101.10 in after-hours trade. A gradual decline in tablet demand worldwide has worried investors already concerned with Apple's slowing growth, who are awaiting a new device that can energize its expansion.

    13 mins ago
  • The New Sedan that Stands out from the Crowd

    Incredible driving with incredible fuel efficiency is now a reality. New 2015 Models have just arrived! Search online for dealer inventory.

    AdChoicesMazda USASponsored
  • Asian share gains fade as China data fail to temper growth anxiety

    China's gross national product expanded 7.3 percent between July and September from a year earlier, slightly above expectations but slower than the 7.5 percent clocked in the second quarter. It was also the weakest growth rate in nearly six years, putting at risk Bejing's official annual growth target for the first time in 15 years and adding to worries that China is becoming a drag on the global economy.

    13 mins ago
  • China's growth slowest since global crisis, annual target at risk

    China grew at its slowest pace since the global financial crisis in the September quarter and risks missing its official target for the first time in 15 years, adding to concerns the world's second-largest economy is becoming a drag on global growth. A pick-up in factory output and government confidence that the labor market remains stable were offset by further slowing in the property sector, and economists remained divided on whether or not authorities would step in with major stimulus measures such as interest rate cuts. China's gross domestic product (GDP) grew 7.3 percent in the third quarter from a year earlier, official data showed on Tuesday, the weakest rate since the first quarter of 2009.

    13 mins ago
  • Staples says probing possible payment card data breach

    "Staples is in the process of investigating a potential issue involving credit card data and has contacted law enforcement," company spokesman Mark Cautela said in a statement late Monday. The office-supply retailer disclosed the investigation after security reporter Brian Krebs reported on his blog Krebsonsecurity.com that several banks have identified a pattern of payment card fraud suggesting that several Staples stores in northeastern United States had succumbed to a data breach.

    13 mins ago
  • Ackman, Valeant lawyers say Allergan CEO oversaw campaign to discredit Valeant

    Billionaire investor William Ackman, whose fund is the largest shareholder in Allergan Inc., and Valeant Pharmaceuticals said the botox maker's Chief Executive Officer David Pyott tried to discredit Valeant as it was making a hostile takeover bid, court documents showed. Ackman's hedge fund has been working with Valeant for months to craft a deal for Valeant to buy Allergan, but Allergan has rejected all of Valeant's overtures and tried to find other potential partners to avoid a deal. In the filing with the federal court in Santa Ana, California, lawyers said that Pyott provided false and misleading information about Valeant to investors, failed to disclose Allergan CFO Jeff Edward's resignation in a timely manner, and ignored outside advisors' input when he falsely called Valeant's account "opaque" and "problematic."

    13 mins ago
  • China must accelerate reforms, not rely on fiscal and monetary policy to drive growth: World Bank

    China needs to accelerate reforms and not rely solely on monetary and fiscal policy to drive growth, a top World Bank official said on Tuesday. "I would recommend not really relying more on their macro policy, specifically on the monetary and fiscal side, because it's been done before, especially post the global financial crisis," Managing Director Sri Mulyani Indrawati told Reuters in an interview in Beijing. Indrawati made the comments when asked whether China was reforming fast enough, given that the country posted its weakest economic growth rate in the third quarter since the 2008/09 global financial crisis.

    13 mins ago
  • AbbVie says $55 billion acquisition of Shire officially dead

    AbbVie, which last week said its board of directors had withdrawn its recommendation to proceed with the Shire purchase, blamed the unraveling on last month's rules changes by the U.S. The company's Chief Executive, Richard Gonzalez, on a conference call with investors, said the new rules and possible future changes "created an environment of risk and uncertainty which makes proceeding not in the best interest of our shareholders." In addition to tax benefits, the acquisition would have given AbbVie Shire's portfolio of lucrative medicines for rare diseases and other specialty drugs, lessening the Chicago-based company's dependence on its rheumatoid arthritis treatment Humira - currently the world's top selling drug with annual sales approaching $13 billion.

    13 mins ago
  • 11:15 am - Brunch is served

    Brunch is served at Hamilton’s Soda Fountain & Luncheonette. A delicious BLT with a fried egg and fruit salad on the side.

    AdChoicespricelessgallerySponsored
  • As China gets tougher on fuel economy, some carmakers may be left behind

    SHANGHAI/BEIJING (Reuters) - Chinese automakers from state-owned FAW Co to Zhejiang Geely are racing to sell more eco-friendly cars as they try to meet tough fuel economy rules due next year as part of Beijing's battle against pollution. A technology deficit versus bigger foreign automakers and the cost of developing or obtaining the new technologies needed are likely to speed up consolidation in a fragmented industry of more than 80 registered manufacturers. The Chinese government last week unveiled tough penalties tied to the new fuel economy rules - from naming-and-shaming those who fail to make the grade to restricting production at non-compliant automakers. "Restricting production is a very severe penalty," said He Hui, an analyst at the International Council on Clean Transportation, an adviser to China's government on fuel-economy policies.

    13 mins ago
  • Valeant says may raise Allergan bid; beats on profit

    Valeant CEO Michael Pearson said a possible revised stock and cash bid would be worth more than $200 per share, assuming that Valeant's stock rises, and would include more cash. Allergan stock was up 1.7 percent at $180.45. Valeant's third-quarter results were keenly anticipated for their potential impact on Valeant's bid for Allergan, maker of anti-wrinkle injection Botox. Unlike most quarters in which, according to critics, one-time charges related to acquisitions obscure Valeant's performance, the company made few deals as it stalked Allergan.

    13 mins ago
  • China to pitch high-speed trains to California

    State-backed China CNR Corporation is making a pitch to sell its high-speed trains to California, signaling China's growing export ambitions for such technology after building the world's longest network in just seven years. It marks the first concrete attempt by China to sell high-speed locomotives abroad and establish itself as a credible rival to sector leaders such as Germany's Siemens, Canada's Bombardier and Japan's Kawasaki. CNR, its unit Tangshan Railway and U.S.-based SunGroup USA are submitting an expression of interest to California's $68 billion high-speed rail project for a contract to supply up to 95 trains that can travel as fast as 354 kilometers per hour (221 miles per hour), SunGroup told Reuters. "We believe that high-speed rail is something that China does very well, and it's a product that we can export across the world," SunGroup spokesman Jonathan Sun said in a phone interview, adding that SunGroup, CNR and Tangshan Railway had been working together for four years.

    13 mins ago